Ebola

US-based BioCryst Pharmaceuticals has received an additional $2.4m funding from the National Institute of Allergy and Infectious Diseases (NIAID) to carry dose ranging efficacy study of an intramuscular formulation of BCX4430 in non-human primates to treat Ebola disease.

The company said that plans are in place to start the study within the next few weeks, enabling the understanding of BCX4430’s potential as a treatment for Ebola disease in humans.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In September 2013, BioCryst secured a $22m contract from NIAID, part of the National Institutes of Health, to conduct the efficacy study.

"Plans are in place to start the study within the next few weeks, enabling the understanding of BCX4430’s potential as a treatment for Ebola disease in humans."

The BCX4430 development contract was increased to $24.4m with the additional funding, which will be provided in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services.

BCX4430 is an RNA dependent-RNA polymerase inhibitor, which showed broad-spectrum activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.

The company is developing BCX4430 by collaborating with US Government Agencies following the Animal Rule regulatory pathway.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BioCryst has designed the BSAV research programme to develop broad-spectrum parenteral and oral therapeutics to treat virus-related diseases.

In the first half of August, NIAID exercised additional options for BioCryst to advance the development of BCX4430 as a treatment for haemorrhagic fever viruses.

Image: Colourised transmission electron micrograph (TEM) revealed some of the ultrastructural morphology displayed by an Ebola virus virion. Photo: courtesy of CDC/Cynthia Goldsmith.